Prevalence
==========

There has been an increase in the concern about preventing the most usual type of diabetes, type 2 diabetes mellitus (T2DM). The public health burden of T2DM has been powerfully increased throughout the world, because T2DM remains a progressive disease. T2DM affects about 5% of Western populations and an estimated 170 million individuals worldwide ([@b127]). In the US, the prevalence of T2DM increased 33% from 1990 to 1998 ([@b79]), was accountable for an estimated US\$132 billion in direct and indirect costs in 2002 and T2DM is the fifth leading cause of death ([@b2]). Moreover, the lifetime risk for developing T2DM was estimated to be 32.8% and 38.5%, respectively, for a man and a woman born in 2000 in the US ([@b81]). Not only the relatively great prevalence at present, but also the alarming increase in T2DM incidence in the coming decades, possibly caused by changes in human environment, lifestyle, and genetic susceptibility, can give rise to a global health problem. The number of diabetic individuals -- the majority of them with T2DM -- is projected to double, reaching about 350 million by the year 2025 ([@b52]) and 360 million by 2030 ([@b127]). By the reason of the escalating rate of T2DM and metabolic syndrome, is expected a concomitant increase in cardiovascular morbidity and mortality, coronary artery disease, end-stage renal disease, blindness, and lower extremity amputations ([@b53]; [@b94]).

Obesity and type 2 diabetes
===========================

The pathogenesis of T2DM within the perception of the metabolic syndrome has been considered by Reaven in his Banting lecture (1988). He postulated that insulin resistance and consequent hyperinsulinemia could be the mutual pathological antecedents of the cardiovascular atherosclerotic pathological conditions ([@b97]). It is well known that the risk of developing clinical T2DM is strongly enhanced in the state of impaired glucose regulation or pre-diabetic states (impaired fasting glycemia or impaired glucose tolerance) and also the risk of developing cardiovascular complications is increased in these early states of glucose intolerance ([@b120]). In the impaired glucose tolerance state, postprandial blood glucose levels are moderately elevated, while on the contrary, fasting blood glucose can generally be maintained within the normal or near-normal range.

All-cause mortality associated with the pre-diabetic states is almost 2 times higher compared with normal glucose tolerance, and mortality per 1000 person-years is 20.8% and 40.9%, respectively, for impaired glucose tolerance and for T2DM ([@b104]). Despite the fact that impaired glucose tolerance is frequently unrecognized, 17% of overweight Americans may have this state ([@b9]). According to an expert guideline, the American Diabetes Association advises physicians taking into account screening for T2DM subjects with risk factors such as family history, overweight, gestational diabetes and hypertension ([@b32]). Menopause ([@b132]) and hyperlipidemia ([@b3]) are factors that also increase the risk of T2DM.

Comparably, the prevalence of obesity is also rising, with more than 60% of Americans, more than 50% of Europeans and Australians, and more than 40% of Brazilians contemporarily classified as overweight ([@b80]; [@b131]; [@b54]). Between 1992 and 2002, the prevalence of overweight and obesity increased in all gender and age groups in China. The combined prevalence of overweight and obesity increased from 14.6% to 21.8% ([@b125]). The increase in prevalence in China over the last 20 years was 400% (APCSC 2007). Obesity is the most important single risk factor for T2DM. Epidemiologic studies suggest that obesity and inactivity are substantial predictors for the development of T2DM among women ([@b50], [@b51]).

The Nurses' Health Study established that a body mass index (BMI) in the upper normal range was correlated with an increased risk of T2DM. Women with a BMI of 35 kg/m^2^ or more had almost a 40-fold risk to develop T2DM compared with women with BMI lower than 23 kg/m^2^. This study also documented that weight change has a powerful influence on the risk of T2DM. A weight gain between 11 and 19.9 kg after 18 years of age represented a more than 5-fold risk of developing T2DM ([@b18]). Comparable information was documented for men in the Health Professionals' Study. In this study, data from a cohort of 51,529 US adult male health professionals were analyzed and individuals with a body mass index (BMI) of 35 kg/m^2^ or more had a 42-fold relative risk to become T2DM compared with men with BMI lower than 23 kg/m^2^. Moreover, waist circumference in the highest quintile was directly correlated to T2DM risk ([@b16]).

Indeed, obesity and particularly intraabdominal adiposity with visceral fat deposition, is one modifiable risk factor directly involved in the increased prevalence of T2DM ([@b117]). Visceral adipocytes have a higher metabolic turnover rate than peripheral adipocytes and the free fatty acids (FFA) are released in high concentrations and drained straight to the liver via the portal vein. Free fatty acids reduce insulin clearance and increase hepatic glucose production. Diminishing body fat has been show to slow the progression of impaired glucose tolerance to T2DM ([@b51]). The risk of T2DM development in individuals with the central pattern of fat distribution is higher than the risk in individuals with a gluteal-femoral or peripheral type of fat distribution ([@b62]). A study of Japanese Americans evidenced that CT-mensurated intraabdominal fat area persisted a significant predictor of T2DM incidence still after adjustment for BMI, total body fat area and other risk factors for T2DM ([@b11]).

Visceral fat is the source of a number of substances which might play a role in the development of a cronic inflammatory ([@b24]) and insulin-resistant state ([@b14]), as well as inadequate survival of pancreatic beta cells ([@b30]). These are interrelated metabolic abnormalities that are the root in the etiology of T2DM. Among these are tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), resistin, visfatin, and adiponectin ([@b10]). The levels of these adipocytokines can be modulated by weight loss, with associated changes in insulin sensibility ([@b20]). Hypoadiponectinemia may contribute to several aspects of the metabolic phenotype of specific ethnic groups, particularly, an increased central obesity and visceral fat and a remarkable increased risk of T2DM ([@b98]). Therefore, therapeutic strategies reducing pro-inflammatory cytokines and/or raising anti-inflammatory adiponectin may have a favorable effect in selected individuals.

Moreover, there is now evidence that impaired adipogenesis, adipocyte hypertrophy and pro-inflammatory factors may have an important role in the pathogenesis of T2DM. In fact, during positive energy balance, energy is stored as body fat, which serves important purposes, such as the release of fatty acids during fasting states, thus allowing fat oxidation by skeletal muscle. The storage of fat (lipogenesis) is first accomplished through enlargement of fat cells (hypertrophy). Further storage requires the recruitment, proliferation and differentiation of adypocites (adipogenesis). If adipogenesis is impaired, progressive adipocyte hypertrophy would lead to metabolic diseases related to excessive fat accumulation, among them T2DM ([@b7]; [@b8]).

Physical activity and type 2 diabetes
=====================================

In addition to adiposity, physical activity is also a modifiable risk factor for T2DM. Individuals who are dynamical and active have a low prevalence of T2DM. However, if they they make a rapid shift from traditional rural active lifestyle to a modern western urbanized sedentary lifestyle, incidence of T2DM boosts ([@b63]). This phenomenon could be seen in Pima Indians ([@b63]), in the South Asian population in the UK ([@b75]), but also in Japanese immigrants in the Southwest of Brazil ([@b34]). Physical activity straightly enhances insulin-dependent glucose removal by the skeletal muscle, reduces visceral fat mass, and consequently improves insulin resistance ([@b66]). In fact, a more recent analysis of the Nurses' Health Study, including 84,941 female nurses followed for 16 years, showed that women with a health lifestyle had a much lower risk of developing T2DM than the general population. Women who exercised at least 7 hours per week reduced the risk of T2DM by 39% compared with women who exercised less than half hour per week ([@b51]). In 7735 British men who were 40 to 59 years of age, moderate physical activity substantially diminished the risk of T2DM relative to sedentary men, after adjustment for BMI and age ([@b91]).

An interesting recent health examination compared the age- and gender-adjusted prevalence of T2DM, obesity and lifestyle in two populations of Pima Indians that share considerable genetic similarity, but do not share the same environment: one living in the traditional environment in the Sierra Madre Mountains of Mexico and the other living in a western environment in Arizona, USA. The prevalence of T2DM in the Mexican Pima Indians was 6.9%, less than one-fifth that in the US Pima Indians (38%) and similar to that of non-Pima Mexicans (2.6%). The prevalence of obesity was comparable in the Mexican Pima Indians (7% in men and 20% in women) and non-Pima Mexicans (respectively 9% and 27%), but much lower than in the US Pima Indians (respectively 64% and 75%). Levels of physical activity were much higher in both Mexican groups than in US Pima Indians ([@b107]).

Dietary factors and type 2 diabetes
===================================

Dietary factors certainly play a role as another modifiable risk factor for T2DM. In the Health Professionals study, a diet high in whole grains was associated with a lower risk of T2DM ([@b37]). The consumption of a diet rich in vegetables, fruit, fish, poultry and whole grains leads to a diminished risk of developing T2DM, when compared to a high consumption of a typical western diet based in red and processed meat ([@b38]), dairy and high-fat ingredients ([@b77]; [@b122]). A large cross-sectional study documented that a 40 g enhancement in daily fat intake yielded an increased risk of impaired glucose tolerance and T2DM, but it is not clearly evident if this increased risk is conditioned to the obese state or to the fat ingestion ([@b74]). The identification of risk factors is basic for the favorable implementation of prevention programs ([Table 1](#tbl1){ref-type="table"}).

###### 

Modifiable and nonmodifiable risk factors for implementation of T2DM prevention programs

  Modifiable factors                                                         Non-modifiable factors
  -------------------------------------------------------------------------- ------------------------------------------------
  Obesity (mainly abdominal adiposity)                                       Ethnicity
  Physical inactivity                                                        Age
  Smoking                                                                    Gender
  Low fiber content of the diet                                              Genetic factors
  High saturated fat/high trans fat in the diet/high processed meat intake   Prior glucose intolerance/gestational diabetes
  Low magnesium intake                                                       Low birth weight
  Low coffee/alcohol intake                                                  Hypertension
  Psychosocial stress                                                        High triglyceride/Low HDL cholesterol

Lifestyle modification is likely to have important effects on the morbidity and mortality of diabetes and should be recommended to all high-risk people. Recent results from the Finnish Diabetes Prevention Study showed that lifestyle interventions to prevent T2DM in men and women with impaired glucose tolerance are cost-effective ([@b68]), although the program used in the DPP study was too expensive for a national program to be implemented ([@b28]).

T2DM is, therefore, a heterogeneous and polygenic disorder. Although our understanding of the etiology and pathogenesis of this disease is not complete, it is known that T2DM is the result of both insulin resistance and relative insulin deficiency ([@b29]; [@b126]). Insulin resistance is a fundamental defect known to precede the onset of T2DM by many years. In some subjects, beta-cells counterbalance for insulin resistance by enhanced insulin secretion and T2DM does not develop. Nevertheless, in many pre-diabetic individuals, beta-cell compensation to insulin resistance is ineffectively performed, and a hyperglycemic condition is generated.

Nonpharmacological modes of T2DM prevention
===========================================

A huge number of studies address several forms by which T2DM could be prevented. Lifestyle changes, food intake modifications -- for instance, lowering the fat content ([@b71]; [@b122]) or enhancing the fiber and magnesium content of the diet ([@b70]) -- and/or physical activity promoting weight loss ([@b31]; [@b86]; [@b110]; [@b117]; [@b64]; [@b65]), smoking status ([@b118]), moderate coffee ([@b123]) and moderate alcohol consumption ([@b19]), and finally bariatric gastric surgery ([@b109]) may be of benefit in the prevention of T2DM in morbidly obese patients ([@b39]).

These data lend powerful credence to the significant weight of lifestyle changes in T2DM prevention, but regardless of the fact that these modifications look to be operative in the prevention, it is highly questionable if these interventions would be sustained for the long-term. By the other hand, it is very clear that health providers need to assist their overweight patients with weight control ([@b116]).

Pharmacological modes of T2DM prevention: antidiabetic, antihypertensive, hypolipidemic agents; hormone replacement therapy
===========================================================================================================================

In addition to lifestyle modifications and education, many oral antidiabetic agents have been evaluated in the context of T2DM prevention, showing reduction of incident T2DM. Although these *post hoc* analysis arouse interest and provocative reaction, these agents are glucose-lowering drugs, so that the clinical benefits in undoubtedly preventing T2DM has yet to be proved. Among there antidiabetic agents are: metformin in the US DPP Study ([@b64]), and possibly in the mid-term 3-year analysis of the ongoing EDIT trial ([@b106]); troglitazone in the TRIPOD interventional study in Hispanic women with a history of gestational diabetes ([@b13]); acarbose in the STOP-NIDDM trial ([@b17]), and also likely in mid-analysis of the EDIT trial ([@b106]), and rosiglitazone in the recently published DREAM trial ([@b27]).

Also the role of blood pressure lowering agents has been studied in the prevention of T2DM in hypertensive patients. The rate of T2DM development was lower among ramipril-treated subjects in the HOPE trial ([@b44]), among captopril-treated patients in CAPP study ([@b43]) and among lisinopril-treated individuals in ALLHAT trial ([@b1]), expressing the well-known insulin sensitizing effect of angiotensin-converting-enzyme inhibitors, but also showing unfavorable effects of the conventional therapy (diuretics or beta-blockers). Compared to atenolol, losartan reduced the new incident cases of T2DM in the LIFE study ([@b21]), but a possible limitation is that atenolol seems to promote T2DM, and hence, it is not possible to evaluate how protective losartan was. In the VALUE trial, valsartan reduced the risk of T2DM, when compared to amlodipine ([@b56]). Treatment with candesartan decreased T2DM incidence in the ALPINE study in newly detected hypertensives ([@b69]) and also in the CHARM trial in patients with heart failure ([@b134]). Compared to diuretics, the rate of T2DM occurrence was lower among nifedipine-treated patients in INSIGHT study ([@b73]) and with amlodipine-treated individuals in the ALLHAT trial ([@b1]), may be reflecting adverse effects of diuretics or beta-blockers rather than beneficial effects of calcium channel blockers. Similarly, amlodipine (adding perindopril as required) in the ASCOT trial induced less T2DM than the combination atenolol and bendroflumethiazide ([@b22]), and in the INVEST study a verapamil plus trandolapril-based regimen reduced the risk of new T2DM compared with a treatment based on hydrochlorothiazide plus atenolol ([@b90]).

The role of hypolipidemic agents in T2DM prevention was assessed. In the WOSCOPS study with pravastatin, a reduction of incident T2DM was observed ([@b36]) and the same was observed in the BIP study with bezafibrate retard ([@b112]).

The answer to the query whether hormone replacement therapy is a feasible way to T2DM prevention persists uncertain. Although the risk of T2DM increased with the duration of estrogen use in Strong Heart study with postmenopausal American Indian women ([@b137]), a reduction in incident T2DM was detected with a combination of conjugated estrogen and medroxyprogesterone acetate in the HERS study with women with coronary heart disease ([@b57]).

Pharmacological modes of T2DM prevention: antiobesity agents
============================================================

As formerly affirmed, a modest 10% weight reduction ([@b31]; [@b86]; [@b110]; [@b117]; [@b64]; [@b65]) and larger weight reduction through gastric surgery ([@b109]; [@b93]) predict a reduced risk of T2DM. So, effective obesity therapies could improve glycemic status and prevent new T2DM ([@b84]; [@b85]).

It is reasonable to conclude that weight reduction with effective antiobesity agents ([@b42]) may contribute to delay or prevent the progression from impaired glucose tolerance to overt T2DM in at risk obese individuals, but this datum is not available with most drugs used to treat obesity. A large long-term prospective study is ongoing with over 9000 patients (the Sibutramine Cardiovascular and diabetes OUTcome study) to examine wether or not sibutramine reduces the risk for cardiovascular complications in subjects at high risk for heart disease and should better determine the place of sibutramine in the prevention of T2DM (although T2DM is not a predefined endpoint of the study) ([@b55]). Another ongoing randomized double-blind placebo-controlled trial (CRESCENDO) of rimonabant for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors may determine if treatment with rimonabant can prevent T2DM (though it is not a predefined endpoint) (see <http://www.clinicaltrials.gov/ct/show/NCT00263042?order=2>).

Orlistat is a specific and strong oral inhibitor of gastrointestinal lipase activity, achieving a 47% to 91% gastric lipase inhibition and a 51% to 82% pancreatic lipase inhibition in healthy volunteers ([@b15]). These lipases are responsible for the hydrolysis of ingested triglycerides into fatty acids and monoglycerides, which are therefore absorbed by the enterocytes. Orlistat has insignificant or no activity against phospholipases, chymotrypsin, trypsin and amylase. By orlistat action, ingested fat absorption is reduced by approximately one third and the nonabsorbed unbroken triglycerides, as well as orlistat, are eliminated in the feces ([@b40]). Orlistat has no systemic action, due to its minimal limited absorption ([@b138]).

The efficacy of orlistat in body weight reduction and long-term management of obesity has been shown in two large multicentre randomized double-blind 2-year trials, with 1187 ([@b108]) and 743 obese patients ([@b25]). At the end of this study, patients receiving orlistat had lower plasma insulin levels compared to the levels at the beginning of the trial while these levels were not significantly different in placebo-treated patients (64.5 vs 84.0 pmol/L and 86.4 vs 86.3 pmol/L, respectively, p = 0.04 between treatment groups). In the same study, the orlistat group had a lower increase in fasting serum glucose levels than the placebo group ( +0.06 mmol/L +vs 0.26 mmol/L, respectively, p = 0.001 between treatment groups). Furthermore, at the end of the multicentre European study ([@b108]), orlistat also generated greater improvements in serum insulin and glucose levels after 1 and 2 years, when compared to the placebo group.

One European study assessed the impact of orlistat on weight loss, glycemic control and serum lipid levels in 391 obese patients with T2DM on sulphonylurea medications for one year and concluded that it is an effective treatment ([@b48]). Comparable results were achieved by [@b60] in obese diabetic patients on insulin and by [@b78] in obese diabetic patients on sulphonylurea or metformin. [@b78] also reported that 1-year treatment with orlistat was associated with significant improvement in blood pressure in orlistat-treated subjects, as well as greater improvements in total cholesterol and LDL cholesterol compared with placebo in overweight and obese patients with T2DM treated with metformin, consistent with the reduction in LDL/HDL ratio documented in many studies ([@b108]; [@b100]; [@b60]; [@b41]). In these studies, all participants were encouraged to adhere to a low fat, weight reduction diet. One Latin-American trial of orlistat evaluating improvement in glycemic profile in obese diabetic patients demonstrated that subjects treated with orlistat plus a mildly controlled energy diet counseling for six months lost significantly more weight than those treated with placebo plus diet, and that, in addition, orlistat treatment was associated with greater improvements in diabetic metabolic parameters, lipid profile and anthropometric risk factors ([@b41]). Another 6-month study in a cohort of severely young obese diabetic Chinese patients reduced the levels of glycosylated hemoglobin and fasting plasma glucose ([@b114]). In general, these studies showed that more patients in the orlistat group than in placebo group either reduced or discontinued one or more antidiabetic drugs or reduced insulin dose and, in opposition, more placebo-treated patients, compared with orlistat-treated subjects required supplemental dosages of antidiabetic medications. The improvements in glycemic profile accomplished in orlistat-treated diabetic individuals in some studies ([@b41]; [@b26]) can be comparable to those documented in trials with antidiabetic medications ([@b46], [@b47]; Johansen 1999).

These observations suggest that orlistat may be an efficient and a safe adjunct to dietary intervention and conventional antidiabetic pharmacotherapy in the global treatment of obese diabetic patients and several meta-analyses have concluded that orlistat is effective in the treatment of T2DM in obese patients ([@b58]; [@b105]).

An initial effort to state that anti-obesity drugs could prevent T2DM was a multicenter evaluation of orlistat, a pooled *post hoc* analysis (n = 675 obese adults with impaired glucose tolerance treated for a men follow-up of 582 days) of three randomized, placebo-controlled clinical trials ([@b45]). Obese nondiabetic individuals received either orlistat (120 mg three times a day with food) or placebo for two years, combined with a mild low energy diet. In orlistat group, less subjects with impaired glucose tolerance at baseline developed T2DM (3%) compared to subjects in placebo group (7.6%). Moreover, considering individuals with impaired glucose tolerance, fasting glucose levels normalized in more orlistat-treated patients than in placebo-treated subjects (respectively, 72% vs 49%, p = 0.04). These findings denote that orlistat treatment has a more favorable effect than placebo on carbohydrate metabolism and can prevent T2DM onset in obese individuals with impaired glucose tolerance at baseline. This report was a retrospective meta-analysis and confirmation of the results by prospective trials was needed.

This ratification came from the XENDOS study ([@b115]), a prospective multicenter randomized double-blind, placebo-controlled, parallel group study, performed in Sweden over a period of four years, aimed to investigate the effectiveness of orlistat plus lifestyle changes compared with lifestyle modifications alone in 3 305 patients with BMI ≥30 kg/m^2^, for T2DM prevention. This is one important difference between XENDOS study and other prevention studies: both groups in XENDOS were prescribed intensive lifestyle modifications, besides receiving either a placebo or an active treatment. Non-diabetic subjects were enrolled, 21% with impaired glucose tolerance, 79% with normal glucose tolerance and randomized to orlistat (120 mg three times a day with meals) or matched placebo. The average compliance with the study drug from first dose until treatment termination was 93% for orlistat patients and placebo patients. Overall, 4% of placebo patients and 8% of orlistat patients withdrew from the study because of adverse events or laboratory abnormalities (mainly due to gastrointestinal events). A diet was prescribed with an intense daily calorie deficit of 800 kcal from the estimated total daily energy expenditure. In addition, all individuals were encouraged to participate in moderate daily physical exercise. A 75 g oral glucose tolerance test was performed at baseline and every six months ([@b115]).

Weight loss was greater in orlistat group (--6.9 kg, n = 1640 completers; --5.8 kg in LOCF analysis) than in placebo group (−4.1 kg, n = 1647 completers; −3 kg in LOCF analysis, p = 0.001). Regional body composition study with computerized tomography at the fourth lumbar vertebra showed significant visceral adipose tissue reduction in orlistat-treated patients, but not in placebo-treated patients ([@b12]). It is remarkable that the placebo group was treated with lifestyle modifications and lost an expressive amount of weight throughout the study, comparable with that in intensive lifestyle intervention branches of other preventive studies (Tuohmilehto et al 2001; [@b64]). In spite of that, the difference in weight loss between groups was able to diminish T2DM incidence (6.2% in orlistat-treated patients vs 9.0% in placebo-treated subjects, p = 0.003, RR reduction = 37.3%). Moreover, the weight loss achieved by patients with impaired glucose tolerance with orlistat plus lifestyle intervention was comparable to that of normal glucose tolerance subjects ([@b115]).

In obese individuals with impaired glucose tolerance, the conversion rate to T2DM was 28.8% in placebo-treated patients vs 18.8% in orlistat-treated patients (p = 0.002, RR reduction = 45%) ([Figure 1](#fig1){ref-type="fig"}). Since the accumulative incidence of T2DM in subjects with normal glucose tolerance at baseline was low, no difference was perceptible between orlistat-treated and placebo-treated individuals in this subgroup. In spite of this, there was a significant reduction in fasting insulin levels at the end of first and fourth year in the orlistat-treated population (p \< 0.001 between treatment groups) ([@b115]). The accumulative occurrence of T2DM in placebo-treated patients with impaired glucose tolerance (14.2%) was comparable to that of the intensive lifestyle intervention arms of other preventive studies (11% and 14.4%) ([@b117]; [@b64]), but the inclusion of orlistat to lifestyle changes reduced incident T2DM in individuals with impaired glucose tolerance by more than 50% when compared with placebo-treated patients ([@b115]). The number of obese patients with impaired glucose tolerance needed to be treated (NNT) with orlistat plus lifestyle changes (rather than lifestyle changes alone) to avoid one case of T2DM was 10, but considering all participants, NNT was 36/4 years. XENDOS was the first study to illustrate that the anti-obesity agent orlistat plus lifestyle changes were able to improve weight loss and reduce incident T2DM in obese individuals above the result achieved with implementation of lifestyle modifications alone over four years. The preventive effect of orlistat in the studied subjects was mainly attributable to its favorable influence on individuals with impaired glucose tolerance.

![Incidence of T2DM by study group in XENDOS study. Cumulative incidence is shown in all obese patients and only in obese patients with impaired glucose tolerance at baseline. The decrease in the risk of developing diabetes with orlistat plus lifestyle intervention compared with placebo plus lifestyle intervention is indicated. *P* values shown are for the log-rank test. Copyright © 2004. Reproduced with permission from [@b115]. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care*, 27:155--61. Erratum in: *Diabetes Care*, 2004 27:856.](vhrm0402-325-01){#fig1}

Another recently published study evaluated efficacy of orlistate in the maintenance of weight loss over 3 years following a major weight loss induced by very-low-energy diet (VLED) in abdominally obese patients with metabolic risk factors such as dyslipidemia, impaired fasting glucose and diet-treated T2DM. The addition of orlistate to lifestyle intervention was associated with maintenance of an extra 2.4 kg weight loss after VLCD for up to 3 years and with a reduced occurrence of T2DM ([@b99]).

Changes in inflammatory mediators TNF-α and IL-6 were evaluated before and after one year of treatment with orlistat and placebo in obese subjects. Weight reduction was associated with diminished levels of TNF-α and IL-6 in both groups, but at the end of the study, TNF-α and IL-6 levels were lower in orlistat-treated subjects ([@b101]). A significant reduction in leptin and high sensitive C-reactive protein, greater in orlistat-treated than in placebo-treated patients was documented by Hsieh et al (2004) in a one-year study with 180 overweight individuals.

Another 6-month trial compared orlistat- and sibutramine-treated morbidly obese women, and documented that, although orlistat group achieved a mean weight loss of 2.5% (nearly half of the weight loss of the sibutramine group) and did not show significant change in metabolic parameters, surprisingly there was a greater and significative decrease of resistin associated with comparable increase in adiponectin ([@b121]). A significant increase in adiponectin in orlistat-treated patients was also observed by Hsieh and colleagues (2004).

It is known that a single dose of orlistat, given before a relatively high fat content meal in overweight patients with T2DM is associated with lower postprandial levels of plasma FFA compared with placebo ([@b111]) and, since the publication of Randle's original hypothesis ([@b95]), many satisfactory and convincing studies have confirmed that plasma levels of FFA can modulate the severity of insulin resistance in T2DM, inhibiting whole body glucose utilization and oxidation ([@b33]; [@b92]; [@b96]; [@b102]; [@b59]).

A huge body of data documents that the clinical benefit for the obese patient with T2DM usually depends on the extent of weight loss ([@b129], [@b130]; [@b128]). A very interesting 6-month trial examined weight loss-dependent and independent effects of orlistat, using behavioral intervention combined with placebo- controlled treatment with orlistat. Even though weight loss was nearly similar in orlistat and placebo-treated patients (nearly 10% of baseline weight), and despite highly comparable changes in regional adiposity, including almost identical decrements of visceral adipose tissue, hepatic steatosis, and skeletal muscle fat content, improvement in insulin sensitivity measured by euglycemic hyperinsulinemic clamp was significantly greater with orlistat therapy ([@b61]). This study showed that the improvement in insulin sensitivity was not related only to the negative energy balance and loss of adipose tissue, factors that did not account for the differential effect, because the rates and amounts of weight loss in both arms of the intervention were highly comparable. A differential treatment effect on plasma FFA likely contributed to the differences in the insulin sensibility status: there was greater reduction in fasting hyperinsulinemia and also in fasting and insulin-suppressed plasma FFA in subjects receiving orlistat, probably related to effects on triglyceride absorption and postprandial lipemia, effect that persisted significant even after statistical adjustment for weight loss. Plasma FFA levels were a strong correlate of insulin sensitivity both before and after weight loss.

Another possibility is an incretin response to orlistat treatment. In fact, the reduced absorption of fat and the increase in intestinal fat content may lead to increased secretion of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) ([@b113]), gut hormones that are secreted in response to food intake, and stimulate insulin secretion ([@b124]). Orlistat increases postprandial GLP-1 levels, enhancing the insulin secretory response to the meal and blunting the postprandial rise in glucose in obese patients with T2DM. The increased GLP-1 levels, which lead to decreased food intake, may also contribute to the weight loss that is associated with the use of orlistat ([@b23]).

Whether these findings provide a physiopathological basis for the benefits in carbohydrate metabolism associated to the weight loss itself, to the limited absorption of lipids and reduction of plasma FFA, to increased production of incretins or to modulation of secretion of cytokines by fat cells ([Table 2](#tbl2){ref-type="table"}), all achieved by treatment with orlistat and lifestyle changes remains to be elucidated.

###### 

Evidence for the benefits in carbohydrate metabolism and T2DM prevention achieved with orlistat treatment

  Putative factor implicated in T2DM prevention with orlistat   Reference
  ------------------------------------------------------------- ------------------
  Reduction in free fatty acid levels                           [@b111]; [@b59]
  Reduction of proinflamatory adipocytokine levels              [@b101]; [@b121]
  Enhancement in anti-inflammatory adipocytokine levels         [@b121]
  Enhancement in incretin levels                                [@b23]

Genetic components -- as well as behavioral and environmental factors -- modify the risk of occurrence of T2DM and some populations have a higher risk of developing T2DM. Consequently, experiments that involved a rather limited demographic sample may not be promptly generalized to the population as a whole. A proposed strategy is to identify subjects most likely to benefit, or at highest risk to receive an aggressive and maybe multiple drug intervention, universalizing a planned effort at lifestyle interventions at the community level ([@b103]; [@b4]; [@b83]).

Specially with respect to oral hypoglycemic agents, but still in relation to orlistat, whether pharmacological preventive therapy merely postpone or mask the diagnosis of T2DM, instead of put forth an authentic preventive outcome is a critical and uncertain matter. Drugs that reduce plasma glucose levels may only reduce the concentrations to a limit situated below than that demanded for the precise diagnosis of T2DM. To show that T2DM is truly prevented, coming studies need to prove arrest of the pathological processes and since the interval between the beginning of beta-cell impaired function and development of T2DM according to the UK Prospective Diabetes Study (UKPDS) Group is about ten years ([@b119]), surveillance periods will need to be considerably prolonged.

One can infer that probably long-term therapy with agents directed toward prevention of T2DM will be needed and that another important matter is the potential adverse events associated with pharmacological tactic for prevention of T2DM. Gastrointestinal adverse events were partly responsible for discontinuation rates in XENDOS study ([@b115]).

A factor that must be considered in forming a decision about pharmacological T2DM preventive intervention is the cost-effectiveness of the therapy. Although supplementing standard T2DM management with orlistat seems to be a reasonably effective and cost-effective treatment option for overweight patients with T2DM ([@b72]) and for the treatment of obesity if only treatment responders continue treatment ([@b35]; [@b67]), the cost-effectiveness of T2DM preventative intervention with orlistat was not yet documented.

Efforts should be directed to identify individuals with pre-diabetic states, family history of T2DM or high risk ethnic background and, from a public health point of view, preventive measures should ideally be focused in pediatric patients at high risk. In the future, genetic variations, as well as interactions between genetic and environmental pathways ([@b5]; [@b135], [@b136]; [@b88], [@b89]; [@b98]) may turn out T2DM prevention easier, affording the possibility of an individualized preventive measure based on this knowledge ([@b87]). New therapeutic agents with unique mode of action, incretins, stimulate the secretion of insulin, suppress glucagon secretion and increase the mass of pancreatic beta-cells ([@b133]; [@b76]; [@b82]). These agents, exenatide and liraglutide could halt and possibly prevent progression to T2DM, but further studies are certainly needed.

To summarize, an important body of evidence from large clinical trials establishes that T2DM is a preventable disease ([@b3]). XENDOS study presented for the first time that an antiobesity agent in combination with lifestyle interventions over four years is of greater benefit than lifestyle attitude modifications alone, specially in high risk individuals with impaired glucose tolerance resulting in more weight loss and greater amelioration in cardiovascular risk factors.
